Suppr超能文献

相似文献

1
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell. 2007 Aug;12(2):131-44. doi: 10.1016/j.ccr.2007.07.003.
2
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.
Blood. 2010 Apr 29;115(17):3541-52. doi: 10.1182/blood-2009-09-243535. Epub 2010 Jan 6.
4
TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.
J Recept Signal Transduct Res. 2010 Apr;30(2):121-32. doi: 10.3109/10799891003634509.
9
TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor.
J Biol Chem. 2010 Apr 23;285(17):12971-8. doi: 10.1074/jbc.M109.076091. Epub 2010 Feb 25.

引用本文的文献

2
Reduction of TRAF3 by heterozygosity or aging impacts B cell function.
Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2507217122. doi: 10.1073/pnas.2507217122. Epub 2025 Aug 7.
3
Transcription Factors and Methods for the Pharmacological Correction of Their Activity.
Int J Mol Sci. 2025 Jul 2;26(13):6394. doi: 10.3390/ijms26136394.
4
Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma.
Blood Neoplasia. 2024 Jun 10;1(3):100025. doi: 10.1016/j.bneo.2024.100025. eCollection 2024 Sep.
6
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma.
Res Sq. 2025 Apr 15:rs.3.rs-6306816. doi: 10.21203/rs.3.rs-6306816/v1.
7
Inflammation and cancer cell survival: TRAF2 as a key player.
Cell Death Dis. 2025 Apr 14;16(1):292. doi: 10.1038/s41419-025-07609-w.
8
Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma.
Curr Treat Options Oncol. 2025 Mar;26(3):197-212. doi: 10.1007/s11864-025-01295-8. Epub 2025 Mar 5.
9
Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling.
Nat Commun. 2024 Dec 2;15(1):10468. doi: 10.1038/s41467-024-54874-y.
10
Next-Generation Therapies for Multiple Myeloma.
Annu Rev Cancer Biol. 2024 Jun;8:351-371. doi: 10.1146/annurev-cancerbio-061421-014236. Epub 2024 Jan 11.

本文引用的文献

1
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood. 2007 Apr 15;109(8):3177-88. doi: 10.1182/blood-2006-09-044974. Epub 2006 Dec 21.
2
Control of B lymphocyte apoptosis by the transcription factor NF-kappaB.
Immunity. 2006 Dec;25(6):871-83. doi: 10.1016/j.immuni.2006.12.003.
3
Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway.
J Biol Chem. 2007 Feb 9;282(6):3688-94. doi: 10.1074/jbc.M610271200. Epub 2006 Dec 11.
4
Global variation in copy number in the human genome.
Nature. 2006 Nov 23;444(7118):444-54. doi: 10.1038/nature05329.
5
Genome assembly comparison identifies structural variants in the human genome.
Nat Genet. 2006 Dec;38(12):1413-8. doi: 10.1038/ng1921. Epub 2006 Nov 22.
6
Mutations in the NF-kappaB signaling pathway: implications for human disease.
Oncogene. 2006 Oct 30;25(51):6831-43. doi: 10.1038/sj.onc.1209939.
7
Rescue of TRAF3-null mice by p100 NF-kappa B deficiency.
J Exp Med. 2006 Oct 30;203(11):2413-8. doi: 10.1084/jem.20061166. Epub 2006 Oct 2.
8
The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development.
Biochem Pharmacol. 2006 Oct 30;72(9):1161-79. doi: 10.1016/j.bcp.2006.08.007. Epub 2006 Sep 12.
10
Nuclear factor-kappaB in cancer development and progression.
Nature. 2006 May 25;441(7092):431-6. doi: 10.1038/nature04870.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验